Results 31 to 40 of about 51,957 (233)

Drug‐Eluting Bioabsorbable Magnesium Stent

Journal of Interventional Cardiology, 2004
Current stent technology is based on the use of permanent implants that remain life long in the vessel wall, far beyond the time required for the prosthesis to accomplish its main goals of sealing dissection and preventing wall recoil. With the possibility to implant long vessel segments using antiproliferative drugs to prevent restenosis, the ...
Di Mario, Carlo, Griffiths, Huw, Goktekin, Omer, Peeters, Nicolas, Verbist, Jan, Bosiers, Marc, Deloose, Koen, Heublein, Bernhard, Rohde, Roland, Kasese, Victor, Ilsley, Charles, Erbel, Raimund   +11 more
openaire   +2 more sources

Drug Distribution and Stent Retention of Drug Eluting Stents [PDF]

, 2008
In this paper the examinations of drug eluting coronary stents are shown, such as the morphology of the coatings before expansion, drug distribution, the methodology and the value of stent retention.
Balázs, T., Bognár, Eszter, Dobránszky, János, Ring, Gy.   +3 more
core  

Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?

São Paulo Medical Journal
CONTEXT AND OBJECTIVE: The safety and efficacy of drug-eluting stents reduce the need for surgical revascularization. The objective of the present study was to investigate whether paclitaxel or rapamycin-eluting stent are effective in avoiding the need ...
Hernani Pinto de Lemos Júnior, Álvaro Nagib Atallah   +1 more
doaj   +1 more source

Drug-eluting stents: current issues [PDF]

, 2005
Early stent thrombosis occurs in about 1% to 1.5% of patients with drug-eluting stents, very similar to the rate with bare-metal stents. Late stent thrombosis is more of a concern with drug-eluting stents, with an incidence of at least 0.35%.
Ong, A.T.L. (Andrew), Serruys, P.W.J.C. (Patrick)   +1 more
core   +1 more source

Very Late Stent Thrombosis 42 Months after Implantation of Sirolimus-Eluting Stent and Discontinuation of Antiplatelet Therapy

Case Reports in Medicine, 2009
Although safety profiles of sirolimus-eluting stents do not seem to differ in short-to-medium term from those of bare-metal stents, late stent thrombosis after deployment of drug-eluting stents has emerged as a potential safety concern in the era of high-
Dirk Sibbing, Karl-Ludwig Laugwitz, Lorenz Bott-Flügel, Jürgen Pache   +3 more
doaj   +1 more source

Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up

Arquivos Brasileiros de Cardiologia, 2014
Background: Drug-eluting stents have been used in daily practice since 2002, with the clear advantages of reducing the risk of target vessel revascularization and an impressive reduction in restenosis rate by 50%-70%.
Denise Oliveira Pellegrini, Vitor Osório Gomes, Ricardo Lasevitch, Luis Smidt, Marco Aurélio Azeredo, Priscila Ledur, Rodrigo Bodanese, Leonardo Sinnott, Emílio Moriguchi, Paulo Caramori   +9 more
doaj   +1 more source

Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction [PDF]

, 2017
Aims To compare the efficacy and safety of drug-eluting stents vs. bare-metal stents in patients with acute ST-segment elevation myocardial infarction.
Di Lorenzo, Emilio, Dibra, Alban, Dirksen, Maurits T., Kaiser, Christoph, Kastrati, Adnan, Laarman, Gerrit J., Mehilli, Julinda, Menichelli, Maurizio, Percoco, Gianfranco, Pittl, Undine, Schömig, Albert, Seyfarth, Melchior, Spaulding, Christian, Suttorp, Maarten J., Syvänne, Mikko, Tierala, Ilkka, Valgimigli, Marco, Varenne, Olivier, Varricchio, Attilio, Violini, Roberto   +19 more
core  

Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting [PDF]

, 2010
Author Manuscript: 2011 April 14Patients with diabetes mellitus (DM) are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases their likelihood of requiring revascularization.
A Abizaid, A Abizaid, A Bayes-Genis, A Dibra, A Kapur, A Kastrati, A Kastrati, AM Freeman, AS Morss, B Lagerqvist, B Stein, BJ Hoogwerf, BJ Rensing, BR Chaitman, C Berry, C Berry, C Rask-Madsen, C Stettler, C Stettler, D Aronson, D Aronson, D Aronson, D Choi, D Hasdai, DE Cutlip, DE Cutlip, DJ Holmes, Doron Aronson, E Belle Van, E Belle Van, EL Alderman, Elazer R. Edelman, FG Welt, GN Levine, H Osanai, HC Gerstein, I Iakovou, I Moussa, J Aoki, J Daemen, J Daemen, J Machecourt, J Schofer, JA Colwell, JB Hermiller, JD Flaherty, JL Orford, JP Carrozza Jr, K Esposito, KE Kip, KE Kip, KH Mak, KM Detre, L Schwartz, L Zhang, LH Young, LO Jensen, M Jonas, M Sabate, MA Hlatky, ME Farkouh, ME Pfisterer, MG Vandormael, MN Babapulle, N Marx, NE West, P Gum, P Piatti, P Urban, P Wenaweser, PJ Quigley, PW Serruys, R Kornowski, R Seabra-Gomes, R Takeda, RA Corpus, RL Frye, S Elezi, S Goldberg, S Roy, S Windecker, SB King 3rd, SB King 3rd, SB King 3rd, SC Smith Jr, SD Wiviott, SM Haffner, T Sakaguchi, T Takagi, TA Trikalinos, TF Luscher, TF Luscher, The Bypass Angioplasty Revascularization Investigation (BARI), The Bypass Angioplasty Revascularization Investigation (BARI) Investigators, V Legrand, W Weintraub, WE Boden, WE Boden, Y Nishimoto   +98 more
core   +1 more source

Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundThe “very late” clinical outcomes for durable polymer drug‐eluting stents and bare metal stents (BMSs) have been shown to be dissimilar in clinical studies.
Hiroyoshi Mori, Dheeraj R. Atmakuri, Sho Torii, Ryan Braumann, Samantha Smith, Hiroyuki Jinnouchi, Anuj Gupta, Emanuel Harari, Melsi Shkullaku, Robert Kutys, David Fowler, Maria Romero, Renu Virmani, Aloke V. Finn   +13 more
doaj   +1 more source

Drug-eluting stents: long-term safety

Терапевтический архив, 2009
The review concerns the problem of late thromboses of drug-eluting stents and their influence on late prognosis of the patients; presents long-term results of the trial of sirolimus-eluting stents implanted to patients with coronary heart disease ...
Yu A Karpov, A N Samko, V V Buza, Yu A Karpov, A N Samko, V V Buza   +5 more
doaj